Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of TQB2101 in Advanced Hematologic Malignancies
NCT07113925Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2101 in hematologic malignancy, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose-limiting toxicity up to 24 months, Maximum Tolerated Dose up to 24 months and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
TQB2101
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07113925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113925.